Neurelis
Latest round
- Series D
Last raised
- Feb 2021
Total raised
- $142M
Investors
- 5
About Neurelis
Based in the US, Neurelis, Inc.Neurelis, Inc. specializes in developing treatments for neurological disorders, with its headquarters located in San Diego, US. Founded in 2007 by Craig Chambliss, Neurelis has undergone operational changes, focusing on expanding its product offerings. The company has completed 9 deals, with the most recent deal occurring on June 4, 2013, when Biotie Therapies Corp. agreed to acquire Neurelis, with financial terms undisclosed.Neurelis, Inc. specializes in developing innovative solutions for individuals living with neurological conditions, focusing primarily on epilepsy management. Their core product, VALTOCO™, is a nasal spray formulation designed for the rapid treatment of seizure clusters in patients with epilepsy. This non-invasive drug delivery system is developed using Neurelis's proprietary technologies, including Intravail®, ProTek®, and Hydrogel™, enhancing the delivery and stabilization of therapeutic molecules. The company aims to address unmet medical needs by providing effective treatment options for patients and their caregivers, ensuring they can manage their condition while maintaining a quality of life.Neurelis generates revenue primarily through the sale of its flagship product, VALTOCO™, marketed to healthcare providers and distributed through various channels, including pharmacies and hospitals. The revenue model is structured around direct-to-consumer sales and partnerships with healthcare institutions, involving prescription fulfillment for patients experiencing seizure clusters. The company is designing additional therapies aimed at enhancing epilepsy management, although specific release dates are not disclosed. Geographically, Neurelis is targeting expansion into select international markets by 2025.76 mn, will support these strategic initiatives, reinforcing the company’s commitment to improving treatment access for individuals with neurological disorders.
Who invested in Neurelis
5 investors across 3 rounds
See all investors in Neurelis
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Neurelis
Who invested in Neurelis?
Neurelis has 5 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Neurelis raised?
Neurelis has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Neurelis last raise money?
Neurelis's most recent round on record is a Series D, in Feb 2021.
What does Neurelis do?
Based in the US, Neurelis, Inc.
Where is Neurelis headquartered?
Neurelis is headquartered in San Diego, US.
Which VCs invest in companies like Neurelis?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Neurelis's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Neurelis? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.